The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Target Advancement Program, 2022Enhancing N-glycosylation of Glucocerebrosidase and other Lysosomal Enzymes as a Disease Modifying Therapy for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) is an age-related neurological movement disorder characterized by the abnormal aggregation of a protein called α-synuclein (α-syn) in the brain. Normally...
-
Spring 2022 RFP: Proof-of-Concept Testing of PD Therapeutics, 2022Identification and Quantification of Parkinson’s Disease Progression Using Digital Measures from a Wrist-worn Wearable Device - a Retrospective Study
Study Rationale: The combination of digital measures and machine learning (ML) holds great promise for improving critical aspects of Parkinson’s disease (PD) care, practice and research. Earlier PD...
-
Spring 2022 RFP: Proof-of-Concept Testing of PD Therapeutics, 2022Project Title: Clinical Development of PDM608, a Potential Neuroprotective and Anti-inflammatory Long-acting Biologic for Parkinson’s Disease
Study Rationale: Targeting neuroinflammation by increasing T regulatory cell numbers is a promising strategy for treating Parkinson’s disease. We propose a Phase 1 trial in non-PD volunteers for our...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Validating BMPs as Novel Drug Candidates for Parkinson’s Disease
Study Rationale: Neurotrophic factors are prime candidates for the development of disease-modifying therapies, based on their properties to restore and maintain the functional integrity of neurons...
-
Target Advancement Program, 2022Alpha-synuclein Aggregation in the Brainstem: Developing a Model and Discovering a New Biomarker for Parkinson Disease
Study Rationale: Abnormal accumulation of alpha-synuclein (a neuronal protein) in distinct regions of the brain is a well known feature in Parkinson’s disease (PD). A sizeable number of people with PD...
-
Target Advancement Program, 2022Development of an Antibody for Isolating Mitochondria from Preclinical Models and Individuals with Parkinson’s Disease
Study Rationale: Previous research has demonstrated that mitochondria — the energy-generating centers in the cell — are impaired in the brains of people with Parkinson’s disease (PD). However, the...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.